31 research outputs found
NanotecnologÃa aplicada al control de la remodelación cardiaca mediante la regulación de la respuesta inflamatoria en modelos animales de isquemia-reperfusión coronaria.
pre-print7902 K
Ivabradine-Stimulated Microvesicle Release Induces Cardiac Protection against Acute Myocardial Infarction.
Ivabradine can reduce heart rate through inhibition of the current I(f ) by still unexplored
mechanisms. In a porcine model of ischemia reperfusion (IR), we found that treatment with 0.3 mg/kg
Ivabradine increased plasma release of microvesicles (MVs) over Placebo, as detected by flow
cytometry of plasma isolated from pigs 7 days after IR, in which a tenfold increase of Extracellular
Matrix Metalloproteinase Inducer (EMMPRIN) containing (both high and low-glycosylated) MVs,
was detected in response to Ivabradine. The source of MVs was investigated, finding a 37% decrease
of CD31+ endothelial cell derived MVs, while CD41+ platelet MVs remained unchanged. By contrast,
Ivabradine induced the release of HCN4+ (mostly cardiac) MVs. While no differences respect to
EMMPRIN as a cargo component were found in endothelial and platelet derived MVs, Ivabradine
induced a significant release of EMMPRIN+/HCN4+ MVs by day 7 after IR. To test the role of
EMMPRIN+ cardiacMVs (EMCMV), H9c2 cellmonolayers were incubated for 24 h with 107 EMCMVs,
reducing apoptosis, and increasing 2 times cell proliferation and 1.5 times cell migration. The in vivo
contribution of Ivabradine-induced plasma MVs was also tested, in which 108 MVs isolated from
the plasma of pigs treated with Ivabradine or Placebo 7 days after IR, were injected in pigs under IR,
finding a significant cardiac protection by increasing left ventricle ejection fraction and a significant
reduction of the necrotic area. In conclusion ivabradine induces cardiac protection by increasing at
least the release of EMMPRIN containing cardiac microvesicles.post-print1810 K
Ivabradine Induces Cardiac Protection against Myocardial Infarction by Preventing Cyclophilin-A Secretion in Pigs under Coronary Ischemia/Reperfusion.
In response to cardiac ischemia/reperfusion, proteolysis mediated by extracellular matrix metalloproteinase inducer (EMMPRIN) and its secreted ligand cyclophilin-A (CyPA) significantly contributes to cardiac injury and necrosis. Here, we aimed to investigate if, in addition to the effect on the funny current (I(f)), Ivabradine may also play a role against cardiac necrosis by reducing EMMPRIN/CyPA-mediated cardiac inflammation. In a porcine model of cardiac ischemia/reperfusion (IR), we found that administration of 0.3 mg/kg Ivabradine significantly improved cardiac function and reduced cardiac necrosis by day 7 after IR, detecting a significant increase in cardiac CyPA in the necrotic compared to the risk areas, which was inversely correlated with the levels of circulating CyPA detected in plasma samples from the same subjects. In testing whether Ivabradine may regulate the levels of CyPA, no changes in tissue CyPA were found in healthy pigs treated with 0.3 mg/kg Ivabradine, but interestingly, when analyzing the complex EMMPRIN/CyPA, rather high glycosylated EMMPRIN, which is required for EMMPRIN-mediated matrix metalloproteinase (MMP) activation and increased CyPA bonding to low-glycosylated forms of EMMPRIN were detected by day 7 after IR in pigs treated with Ivabradine. To study the mechanism by which Ivabradine may prevent secretion of CyPA, we first found that Ivabradine was time-dependent in inhibiting co-localization of CyPA with the granule exocytosis marker vesicle-associated membrane protein 1 (VAMP1). However, Ivabradine had no effect on mRNA expression nor in the proteasome and lysosome degradation of CyPA. In conclusion, our results point toward CyPA, its ligand EMMPRIN, and the complex CyPA/EMMPRIN as important targets of Ivabradine in cardiac protection against IR.post-print361 K
Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.
Toll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion
(IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we
administered 0.078 mg/kg ApTOLL or Placebo in pigs subjected to IR, analyzing the levels of cardiac
troponins, matrix metalloproteinases, pro-, and anti-inflammatory cytokines, heart function, and tissue
integrity over a period of 7 days after IR. Our results show that ApTOLL reduced cardiac troponin-1
24 h after administration, improving heart function, as detected by a significant recovery of the left
ventricle ejection fraction (LVEF) and the shortening fraction (FS) cardiac parameters. The extension
of necrotic and fibrotic areas was also reduced, as detected by Evans blue/2,3,5-triphenyltetrazolium
chloride (TTC) staining, Hematoxylin/Eosine, and Masson Trichrome staining of heart sections,
together with a significant reduction in the expression of the extracellular matrix-degrading, matrix
metalloproteinase 9. Finally, the expression of the following cytokines, CCL1, CCL2, MIP1-A-B,
CCL5, CD40L, C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INF-g, IL1-a,
ILI-b, IL-1Ra, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32,
MIF, SERPIN-E1, TNF-a, and TREM-1, were also assayed, detecting a pronounced decrease of
pro-inflammatory cytokines after 7 days of treatment with ApTOLL. Altogether, our results show
that ApTOLL is a promising new tool for the treatment of acute myocardial infarction (AMI).post-print3782 K
NIL10: A New IL10-Receptor Binding Nanoparticle That Induces Cardiac Protection in Mice and Pigs Subjected to Acute Myocardial Infarction through STAT3/NF-kB Activation.
Background: Early response after acute myocardial infarction (AMI) prevents extensive
cardiac necrosis, in which inflammation resolution, including expression of anti-inflammatory
interleukin-10 (IL-10), may play a key role. (2) Methods: We synthesized NIL10, a micelle-based
nanoparticle, to target IL-10 receptor in mice and pigs subjected to AMI. (3) Results: Administration
of NIL10 induced cardiac protection of wild-type and IL-10 knockout mice and pigs subjected to AMI.
Cardiac protection was not induced in IL-10-receptor null mice, as shown by a significant recovery of
cardiac function, in which inflammatory foci and fibrosis were strongly reduced, together with the
finding that resolving M2-like macrophage populations were increased after day 3 of reperfusion. In
addition, anti-inflammatory cytokines, including IL-4, IL-7, IL-10, IL-13, IL-16, and IL-27 were also
elevated. Mechanistically, NIL10 induced activation of the IL-10 receptor/STAT-3 signaling pathway,
and STAT3-dependent inhibition of nuclear translocation of pro-inflammatory NF-kB transcription
factor. (4) Conclusions: Taken together, we propose using NIL10 as a novel therapeutic tool against
AMI-induced cardiac damagepost-print4711 K
Legal Cannabis sativa L. Dried Inflorescences: Cannabinoids Content and Cytotoxic Activity against Human HepG2 Cell Line
Cannabis sativa L. has health benefits, principally due to the levels and ratios of two impor- tant cannabinoids, ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC:CBD ratio affects their pharmacological interaction for the treatment of different diseases as well as its modulation allows for a custom-made product that utilizes the distinguishing effects of CBD, THC, or both, for a peculiar patient or clinical effect. This study aims to investigate the total content of THC, CBD, and their ratio in 34 dried inflorescence legally sold in physical and online stores, by using a validated liquid chromatography-ultraviolet (HPLC-UV) method, after cannabinoids identification performed through MSn studies. Cannabinol (CBN) content was also monitored to evaluate hemp age or con- servation status. CBN content always resulted lower than limit of quantification, thus confirming well-stored fresh hemp. All investigated samples showed a total THC amount below 0.59% w/w, thus responding to legal requirements.. The total CBD amount ranged from 2.62 to 20.27% w/w and it was not related to THC level. THC:CBD ranged among 1:3 and 1:26, thus ascertaining their suitability for different target pharmacological uses. In vitro studies using human hepatoblastoma cell line HepG2 suggested that hemp extracts with THC:CBD ratios of 1:9 exhibited higher toxicity than pure cannabinoids
β2M Signals Monocytes Through Non-Canonical TGFβ Receptor Signal Transduction.
Rationale: Circulating monocytes can have pro-inflammatory or pro-reparative phenotypes. The
endogenous signaling molecules and pathways that regulate monocyte polarization in vivo are poorly
understood. We have shown that platelet derived beta-2 microglobulin (β2M) and transforming growth
factor beta (TGFβ) have opposing effects on monocytes by inducing inflammatory and reparative
phenotypes respectively, but each bind and signal through the same receptor. We now define the signaling
pathways involved.
Objective: To determine the molecular mechanisms and signal transduction pathways by which β2M and
TGFβ regulate monocyte responses both in vitro and in vivo.
Methods and Results: Wild-type (WT) and platelet specific β2M knockout (Plt-β2M-/-) mice were treated
intravenously with either β2M or TGFβ to increase plasma concentrations to those in cardiovascular
diseases. Elevated plasma β2M increased pro-inflammatory monocytes, while increased plasma TGFβ
increased pro-reparative monocytes. TGFβ receptor (TGFβR) inhibition blunted monocyte responses to
both β2M and TGFβ in vivo. Using imaging flow cytometry, we found that β2M decreased monocyte
SMAD2/3 nuclear localization, while TGFβ promoted SMAD nuclear translocation, but decreased noncanonical/
inflammatory (JNK and NFκB nuclear localization). This was confirmed in vitro using both
imaging flow cytometry and immunoblots. β2M, but not TGFβ, promoted ubiquitination of SMAD3 and
SMAD4, that inhibited their nuclear trafficking. Inhibition of ubiquitin ligase activity blocked noncanonical
SMAD-independent monocyte signaling and skewed monocytes towards a pro-reparative
monocyte response.
Conclusions: Our findings indicate that elevated plasma β2M and TGFβ dichotomously polarize
monocytes. Furthermore, these immune molecules share a common receptor, but induce SMAD-dependent
canonical signaling (TGFβ) versus non-canonical SMAD-independent signaling (β2M) in a ubiquitin ligase
dependent manner. This work has broad implications as β2M is increased in several inflammatory
conditions, while TGFβ is increased in fibrotic diseases.pre-print3451 K
Antimicrobial Prophylaxis in Neonates and Children Undergoing Dental, Maxillo-Facial or Ear-Nose-Throat (ENT) Surgery: A RAND/UCLA Appropriateness Method Consensus Study
Surgical site infections (SSIs) represent a potential complication in surgical procedures, mainly because clean/contaminated surgery involves organs that are normally colonized by bacteria. Dental, maxillo-facial and ear-nose-throat (ENT) surgeries are among those that carry a risk of SSIs because the mouth and the first respiratory tracts are normally colonized by a bacterial flora. The aim of this consensus document was to provide clinicians with recommendations on surgical antimicrobial prophylaxis in neonates (<28 days of chronological age) and pediatric patients (within the age range of 29 days-18 years) undergoing dental, maxillo-facial or ENT surgical procedures. These included: (1) dental surgery; (2) maxilla-facial surgery following trauma with fracture; (3) temporo-mandibular surgery; (4) cleft palate and cleft lip repair; (5) ear surgery; (6) endoscopic paranasal cavity surgery and septoplasty; (7) clean head and neck surgery; (8) clean/contaminated head and neck surgery and (9) tonsillectomy and adenoidectomy. Due to the lack of pediatric data for the majority of dental, maxillo-facial and ENT surgeries and the fact that the recommendations for adults are currently used, there is a need for ad hoc studies to be rapidly planned for the most deficient areas. This seems even more urgent for interventions such as those involving the first airways since the different composition of the respiratory microbiota in children compared to adults implies the possibility that surgical antibiotic prophylaxis schemes that are ideal for adults may not be equally effective in children
Antimicrobial Prophylaxis for Urologic Procedures in Paediatric Patients: A RAND/UCLA Appropriateness Method Consensus Study in Italy
The main aim of surgical antimicrobial prophylaxis (SAP) in urologic procedures is to prevent bacteraemia, surgical site infections (SSIs), and postoperative urinary tract infections (ppUTIs). Guidelines for SAP in paediatric urology are lacking. Only some aspects of this complex topic have been studied, and the use of antibiotic prophylaxis prior to surgical procedures seems to be more often linked to institutional schools of thought or experts' opinions than to rules dictated by studies demonstrating the most correct and preferred management. Therefore, the aim of this Consensus document realized using the RAND/UCLA appropriateness method is to provide clinicians with a series of recommendations on SAP for the prevention of bacteraemia, SSIs, and ppUTIs after urologic imaging and surgical procedures in paediatric patients. Despite the few available studies, experts agree on some basilar concepts related to SAP for urologic procedures in paediatric patients. Before any urological procedure is conducted, UTI must be excluded. Clean procedures do not require SAP, with the exception of prosthetic device implantation and groin and perineal incisions where the SSI risk may be increased. In contrast, SAP is needed in clean-contaminated procedures. Studies have also suggested the safety of eliminating SAP in paediatric hernia repair and orchiopexy. To limit the emergence of resistance, every effort to reduce and rationalize antibiotic consumption for SAP must be made. Increased use of antibiotic stewardship can be greatly effective in this regard
Surgical Antimicrobial Prophylaxis in Patients of Neonatal and Pediatric Age Undergoing Orthopedic and Hand Surgery: A RAND/UCLA Appropriateness Method Consensus Study
Surgical site infections (SSIs) represent a potential complication in any type of surgery and can occur up to one year after the procedure in the case of implant placement. In the field of orthopedic and hand surgery, the rate of SSIs is a relevant issue, considering the need for the placement of synthesis devices and the type of some interventions (e.g., exposed fractures). This work aims to provide guidance on the management of peri-operative antibiotic prophylaxis for the pediatric and neonatal population undergoing orthopedic and hand surgery in order to standardize the management of patients and to reduce, on the one hand, the risk of SSI and, on the other, the development of antimicrobial resistance. The following scenarios were considered: (1) bloodless fracture reduction; (2) reduction of unexposed fracture and grade I and II exposed fracture; (3) reduction of grade III exposed fracture or traumatic amputation; (4) cruel fracture reduction with percutaneous synthesis; (5) non-traumatic amputation; (6) emergency intact skin trauma surgery and elective surgery without synthetic media placement; (7) elective orthopedic surgery with prosthetic and/or synthetic media placement and spinal surgery; (8) clean elective hand surgery with and without bone involvement, without use of synthetic means; (9) surgery of the hand on an elective basis with bone involvement and/or with use of synthetic means. This manuscript has been made possible by the multidisciplinary contribution of experts belonging to the most important Italian scientific societies and represents, in our opinion, the most complete and up-to-date collection of recommendations regarding the behavior to be adopted in the peri-operative setting in neonatal and pediatric orthopedic and hand surgery. The specific scenarios developed are aimed at guiding the healthcare professional in practice to ensure the better and standardized management of neonatal and pediatric patients, together with an easy consultation